Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
81 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2017 Summary Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol calcium second messenger system and generates a calcium activated chloride current. mGluR5 plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity. Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 26 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 12 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 7 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders and Musculoskeletal Disorders which include indications Dyskinesia, Anxiety Disorders, Autism, Depression, Schizophrenia, Cognitive Impairment Associated With Schizophrenia (CIAS), Major Depressive Disorder, Alcohol Addiction, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Chronic Pain, Cognitive Disorders, Cognitive Impairment, DiGeorge Syndrome, Fragile X Syndrome, Generalized Anxiety Disorder (GAD), Mania, Neurology, Opium (Opioid) Addiction, Pain, Parkinson's Disease, Spasmodic Torticollis and Substance (Drug) Abuse. The latest report Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2017, outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects - The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Overview 8 Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Development 9 Products under Development by Stage of Development 9 Products under Development by Therapy Area 10 Products under Development by Indication 11 Products under Development by Companies 14 Products under Development by Universities/Institutes 17 Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Assessment 19 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 22 Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies Involved in Therapeutics Development 23 Addex Therapeutics Ltd 23 Aevi Genomic Medicine Inc 23 Bristol-Myers Squibb Company 24 Eisai Co Ltd 24 Eli Lilly and Company 25 Heptares Therapeutics Ltd 25 Johnson & Johnson 26 Merz Pharma GmbH & Co KgaA 26 Novartis AG 27 Richter Gedeon Nyrt 27 Sumitomo Dainippon Pharma Co Ltd 28 Toray Industries Inc 28 Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles 29 alloswitch-1 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 BMS-952048 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 BMS-955829 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 dipraglurant ER - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 dipraglurant IR - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 DSR-98776 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 fasoracetam - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 GET-73 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 HTL-14242 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 JNJ-46778212 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 LSN-2814617 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 mavoglurant - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 PAM-12 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Small Molecule to Antagonize mGlu5 for Persistent Pain - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Small Molecule to Antagonize mGluR5 for CNS Disorders - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Small Molecules to Agonize mGluR5 for Schizophrenia - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Small Molecules to Antagonize mGluR5 for Anxiety - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Small Molecules to Antagonize MGLUR5 for Anxiety Disorders - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 VU-0092273 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 VU-0431316 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 VU-0463841 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 VU-0467558 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Dormant Products 62 Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Discontinued Products 65 Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Product Development Milestones 67 Featured News & Press Releases 67 May 10, 2017: Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001 67 Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD 67 Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD 69 Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001 69 Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome 70 Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents 70 Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder 71 Oct 17, 2016: Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia 72 Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD 73 Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society 73 Apr 11, 2016: Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers 74 Mar 15, 2016: Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers 76 Jan 11, 2016: Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept 77 Jan 04, 2016: Addex' Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson's Disease 77 Dec 17, 2015: Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial 78 Appendix 80 Methodology 80 Coverage 80 Secondary Research 80 Primary Research 80 Expert Panel Validation 80 Contact Us 80 Disclaimer 81
List of Tables
Number of Products under Development by Stage of Development, H2 2017 9 Number of Products under Development by Therapy Areas, H2 2017 10 Number of Products under Development by Indications, H2 2017 12 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13 Number of Products under Development by Companies, H2 2017 14 Products under Development by Companies, H2 2017 15 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16 Number of Products under Investigation by Universities/Institutes, H2 2017 17 Products under Investigation by Universities/Institutes, H2 2017 18 Number of Products by Stage and Mechanism of Actions, H2 2017 20 Number of Products by Stage and Route of Administration, H2 2017 21 Number of Products by Stage and Molecule Type, H2 2017 22 Pipeline by Addex Therapeutics Ltd, H2 2017 23 Pipeline by Aevi Genomic Medicine Inc, H2 2017 23 Pipeline by Bristol-Myers Squibb Company, H2 2017 24 Pipeline by Eisai Co Ltd, H2 2017 24 Pipeline by Eli Lilly and Company, H2 2017 25 Pipeline by Heptares Therapeutics Ltd, H2 2017 25 Pipeline by Johnson & Johnson, H2 2017 26 Pipeline by Merz Pharma GmbH & Co KgaA, H2 2017 26 Pipeline by Novartis AG, H2 2017 27 Pipeline by Richter Gedeon Nyrt, H2 2017 27 Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 28 Pipeline by Toray Industries Inc, H2 2017 28 Dormant Products, H2 2017 62 Dormant Products, H2 2017 (Contd..1), H2 2017 63 Dormant Products, H2 2017 (Contd..2), H2 2017 64 Discontinued Products, H2 2017 65 Discontinued Products, H2 2017 (Contd..1), H2 2017 66
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
